Key facts
- This page summarizes Quyen Thi Dao-Haddock's Form 4 filing for BIOCEPT INC.
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 18 Nov 2022, 19:26.
Quyen Thi Dao-Haddock - 17 Nov 2022 Form 4 Insider Report for BIOCEPT INC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 17 Nov 2022
- Net transaction value
- $0
- Reporting owner signature
- /s/ Quyen Thi Dao-Haddock
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Quyen Thi Dao-Haddock filed Form 4 for BIOCEPT INC on 18 Nov 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIOC
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 17 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $0.8100
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
1/3 of the shares subject to the option shall vest on each of November 17, 2023, November 17, 2024, and November 17, 2025.